Evidence map›Paper›PMID 39621254›Full record

ArticleJournal of hematopathology2024

Mast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis.

Nicholas Collins, Nicholas Willard, Zenggang Pan

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nicholas CollinsDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Nicholas WillardDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Zenggang PanDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA. zenggang.pan@cuanschutz.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cell sarcoma (MCS) is an extremely rare and aggressive form of mastocytosis characterized by highly atypical mast cells with local invasion, metastatic potential, and poor prognosis. MCS is predominantly a de novo process without recurrent molecular findings or predisposing lesions including various myeloid neoplasms. However, there have been rare case reports of MCS with preceding or concurrent systemic mastocytosis (SM) or cutaneous mastocytosis (CM), which is suggestive of an uncommon progression from SM/CM to MCS. We hereby report a case of MCS in an 84-year-old male with a KIT p.D816V mutation and concurrent SM. KIT p.D816V point mutation is well known as the canonical variant in SM. In our case, MCS with KIT p.D816V mutation is a unique finding in the setting of concurrent SM, highlighting the potential relatedness of these two entities and the progression from SM to MCS, a currently poorly understood phenomenon.

Indexed as

Mast-Cell SarcomaMastocytosis, SystemicProto-Oncogene Proteins c-kitAged, 80 and overHumansMaleMutationKIT protein, humanProto-Oncogene Proteins c-kitKIT p.D816VMast cell sarcomaSystemic mastocytosis

Identifiers

PMID39621254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.